Global mRNA Vaccines & Therapeutics Market
Global mRNA Vaccines & Therapeutics Market

mRNA Vaccines & Therapeutics Comprehensive Study by Type (Standardization of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine), Application (Hospital, Clinic, Others), Mechanism of Action (Bioengineered Vaccine, Gene Therapy (Gene Silencing/Suppression), Gene Transcription (Protein Generation), Cell Therapy, Monoclonal Antibody, Others) Players and Region - Global Market Outlook to 2025

mRNA Vaccines & Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Aug 2020 Edition 216 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global mRNA Vaccines & Therapeutics Market Overview:
mRNA is a versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use led to transient expression of the encoded protein. This favorable safety profile makes mRNA exclusively attractive for vaccines and gene editing. mRNA is chemically well defined which ensures reproducible manufacturing at high yield, purity and activity. An improvement of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies. Some of the players profiled in the study are Argos Therapeutics (U.S), AstraZeneca (UK), Bayer (Germany), Boehringer Ingelheim (Germany), CRISPR Therapeutics (Switzerland), CureVac (Germany), ETheRNA immunotherapies (Belgium), Ethris (Germany), In-Cell-Art (France) and Intellia Therapeutics (U.S).

On the basis of geography, the market of mRNA Vaccines & Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Mechanism of Action, the sub-segment i.e. Bioengineered Vaccine will boost the mRNA Vaccines & Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Rise in prevalence of chronic diseases like diabetes, tuberculosis, cancer and certain other cardiovascular conditions
  • Government Support provided by various regions

Influencing Trend
  • Rapid advancement in technologies particularly in the healthcare sector

Restraints
  • High failure rated accompanied with problems faced in drug delivery

Opportunities
  • Business dynamics present in Asia Pacific is expected to provide lucrative opportunity

Challenges
  • Expensive research


Key Market Developments:


Key players are implementing various strategies such as mergers & acquisitions, new product development, partnerships and others. Medical technology and healthcare companies are setting standards by providing mRNA vaccines & therapeutics with the help of various technological advancements

Target Audience:
Manufacturers of mRNA vaccines & therapeutics, Suppliers of mRNA vaccines & therapeutics subcomponents, Wholesalers, distributers and retailers of mRNA vaccines & therapeutics, Pharmaceutical industry, Hospitals, Clinics, Research organizations and Governmental bodies

Major Objectives Focused through this Study
• To define, describe, and forecast the Global mRNA Vaccines & Therapeutics market on the basis of product [Standardization of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine and Infection Prevention MRNA Vaccine] , application [Hospital, Clinic and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the mRNA Vaccines & Therapeutics market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the mRNA Vaccines & Therapeutics industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Janssen (Belgium), Kernal Biologics (U.S), MaxCyte (U.S), Moderna Therapeutics (U.S), Novartis (Switzerland), Precision NanoSystems (Canada) and RaNa Therapeutics (U.S).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the mRNA Vaccines & Therapeutics market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Standardization of Cancer Treatment MRNA Vaccine
  • Individualized Cancer Treatment MRNA Vaccine
  • Infectious Disease Treatment MRNA Vaccine
  • Infection Prevention MRNA Vaccine
By Application
  • Hospital
  • Clinic
  • Others
By Mechanism of Action
  • Bioengineered Vaccine
  • Gene Therapy (Gene Silencing/Suppression)
  • Gene Transcription (Protein Generation)
  • Cell Therapy
  • Monoclonal Antibody
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in prevalence of chronic diseases like diabetes, tuberculosis, cancer and certain other cardiovascular conditions
      • 3.2.2. Government Support provided by various regions
    • 3.3. Market Challenges
      • 3.3.1. Expensive research
    • 3.4. Market Trends
      • 3.4.1. Rapid advancement in technologies particularly in the healthcare sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global mRNA Vaccines & Therapeutics, by Type, Application, Mechanism of Action and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global mRNA Vaccines & Therapeutics (Value)
      • 5.2.1. Global mRNA Vaccines & Therapeutics by: Type (Value)
        • 5.2.1.1. Standardization of Cancer Treatment MRNA Vaccine
        • 5.2.1.2. Individualized Cancer Treatment MRNA Vaccine
        • 5.2.1.3. Infectious Disease Treatment MRNA Vaccine
        • 5.2.1.4. Infection Prevention MRNA Vaccine
      • 5.2.2. Global mRNA Vaccines & Therapeutics by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global mRNA Vaccines & Therapeutics by: Mechanism of Action (Value)
        • 5.2.3.1. Bioengineered Vaccine
        • 5.2.3.2. Gene Therapy (Gene Silencing/Suppression)
        • 5.2.3.3. Gene Transcription (Protein Generation)
        • 5.2.3.4. Cell Therapy
        • 5.2.3.5. Monoclonal Antibody
        • 5.2.3.6. Others
      • 5.2.4. Global mRNA Vaccines & Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global mRNA Vaccines & Therapeutics (Price)
      • 5.3.1. Global mRNA Vaccines & Therapeutics by: Type (Price)
  • 6. mRNA Vaccines & Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Argos Therapeutics (U.S)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (UK)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CRISPR Therapeutics (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CureVac (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ETheRNA immunotherapies (Belgium)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ethris (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. In-Cell-Art (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Intellia Therapeutics (U.S)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global mRNA Vaccines & Therapeutics Sale, by Type, Application, Mechanism of Action and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global mRNA Vaccines & Therapeutics (Value)
      • 7.2.1. Global mRNA Vaccines & Therapeutics by: Type (Value)
        • 7.2.1.1. Standardization of Cancer Treatment MRNA Vaccine
        • 7.2.1.2. Individualized Cancer Treatment MRNA Vaccine
        • 7.2.1.3. Infectious Disease Treatment MRNA Vaccine
        • 7.2.1.4. Infection Prevention MRNA Vaccine
      • 7.2.2. Global mRNA Vaccines & Therapeutics by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global mRNA Vaccines & Therapeutics by: Mechanism of Action (Value)
        • 7.2.3.1. Bioengineered Vaccine
        • 7.2.3.2. Gene Therapy (Gene Silencing/Suppression)
        • 7.2.3.3. Gene Transcription (Protein Generation)
        • 7.2.3.4. Cell Therapy
        • 7.2.3.5. Monoclonal Antibody
        • 7.2.3.6. Others
      • 7.2.4. Global mRNA Vaccines & Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global mRNA Vaccines & Therapeutics (Price)
      • 7.3.1. Global mRNA Vaccines & Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. mRNA Vaccines & Therapeutics: by Type(USD Million)
  • Table 2. mRNA Vaccines & Therapeutics Standardization of Cancer Treatment MRNA Vaccine , by Region USD Million (2014-2019)
  • Table 3. mRNA Vaccines & Therapeutics Individualized Cancer Treatment MRNA Vaccine , by Region USD Million (2014-2019)
  • Table 4. mRNA Vaccines & Therapeutics Infectious Disease Treatment MRNA Vaccine , by Region USD Million (2014-2019)
  • Table 5. mRNA Vaccines & Therapeutics Infection Prevention MRNA Vaccine , by Region USD Million (2014-2019)
  • Table 6. mRNA Vaccines & Therapeutics: by Application(USD Million)
  • Table 7. mRNA Vaccines & Therapeutics Hospital , by Region USD Million (2014-2019)
  • Table 8. mRNA Vaccines & Therapeutics Clinic , by Region USD Million (2014-2019)
  • Table 9. mRNA Vaccines & Therapeutics Others , by Region USD Million (2014-2019)
  • Table 10. mRNA Vaccines & Therapeutics: by Mechanism of Action(USD Million)
  • Table 11. mRNA Vaccines & Therapeutics Bioengineered Vaccine , by Region USD Million (2014-2019)
  • Table 12. mRNA Vaccines & Therapeutics Gene Therapy (Gene Silencing/Suppression) , by Region USD Million (2014-2019)
  • Table 13. mRNA Vaccines & Therapeutics Gene Transcription (Protein Generation) , by Region USD Million (2014-2019)
  • Table 14. mRNA Vaccines & Therapeutics Cell Therapy , by Region USD Million (2014-2019)
  • Table 15. mRNA Vaccines & Therapeutics Monoclonal Antibody , by Region USD Million (2014-2019)
  • Table 16. mRNA Vaccines & Therapeutics Others , by Region USD Million (2014-2019)
  • Table 17. South America mRNA Vaccines & Therapeutics, by Country USD Million (2014-2019)
  • Table 18. South America mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 19. South America mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 20. South America mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 21. Brazil mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 22. Brazil mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 23. Brazil mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 24. Argentina mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 25. Argentina mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 26. Argentina mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 27. Rest of South America mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 28. Rest of South America mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 29. Rest of South America mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 30. Asia Pacific mRNA Vaccines & Therapeutics, by Country USD Million (2014-2019)
  • Table 31. Asia Pacific mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 32. Asia Pacific mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 33. Asia Pacific mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 34. China mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 35. China mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 36. China mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 37. Japan mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 38. Japan mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 39. Japan mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 40. India mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 41. India mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 42. India mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 43. South Korea mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 44. South Korea mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 45. South Korea mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 46. Taiwan mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 47. Taiwan mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 48. Taiwan mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 49. Australia mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 50. Australia mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 51. Australia mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 52. Rest of Asia-Pacific mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 53. Rest of Asia-Pacific mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 54. Rest of Asia-Pacific mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 55. Europe mRNA Vaccines & Therapeutics, by Country USD Million (2014-2019)
  • Table 56. Europe mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 57. Europe mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 58. Europe mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 59. Germany mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 60. Germany mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 61. Germany mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 62. France mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 63. France mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 64. France mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 65. Italy mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 66. Italy mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 67. Italy mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 68. United Kingdom mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 69. United Kingdom mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 70. United Kingdom mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 71. Netherlands mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 72. Netherlands mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 73. Netherlands mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 74. Rest of Europe mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 75. Rest of Europe mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 76. Rest of Europe mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 77. MEA mRNA Vaccines & Therapeutics, by Country USD Million (2014-2019)
  • Table 78. MEA mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 79. MEA mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 80. MEA mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 81. Middle East mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 82. Middle East mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 83. Middle East mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 84. Africa mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 85. Africa mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 86. Africa mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 87. North America mRNA Vaccines & Therapeutics, by Country USD Million (2014-2019)
  • Table 88. North America mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 89. North America mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 90. North America mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 91. United States mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 92. United States mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 93. United States mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 94. Canada mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 95. Canada mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 96. Canada mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 97. Mexico mRNA Vaccines & Therapeutics, by Type USD Million (2014-2019)
  • Table 98. Mexico mRNA Vaccines & Therapeutics, by Application USD Million (2014-2019)
  • Table 99. Mexico mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2014-2019)
  • Table 100. mRNA Vaccines & Therapeutics: by Type(USD/Units)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. mRNA Vaccines & Therapeutics: by Type(USD Million)
  • Table 112. mRNA Vaccines & Therapeutics Standardization of Cancer Treatment MRNA Vaccine , by Region USD Million (2020-2025)
  • Table 113. mRNA Vaccines & Therapeutics Individualized Cancer Treatment MRNA Vaccine , by Region USD Million (2020-2025)
  • Table 114. mRNA Vaccines & Therapeutics Infectious Disease Treatment MRNA Vaccine , by Region USD Million (2020-2025)
  • Table 115. mRNA Vaccines & Therapeutics Infection Prevention MRNA Vaccine , by Region USD Million (2020-2025)
  • Table 116. mRNA Vaccines & Therapeutics: by Application(USD Million)
  • Table 117. mRNA Vaccines & Therapeutics Hospital , by Region USD Million (2020-2025)
  • Table 118. mRNA Vaccines & Therapeutics Clinic , by Region USD Million (2020-2025)
  • Table 119. mRNA Vaccines & Therapeutics Others , by Region USD Million (2020-2025)
  • Table 120. mRNA Vaccines & Therapeutics: by Mechanism of Action(USD Million)
  • Table 121. mRNA Vaccines & Therapeutics Bioengineered Vaccine , by Region USD Million (2020-2025)
  • Table 122. mRNA Vaccines & Therapeutics Gene Therapy (Gene Silencing/Suppression) , by Region USD Million (2020-2025)
  • Table 123. mRNA Vaccines & Therapeutics Gene Transcription (Protein Generation) , by Region USD Million (2020-2025)
  • Table 124. mRNA Vaccines & Therapeutics Cell Therapy , by Region USD Million (2020-2025)
  • Table 125. mRNA Vaccines & Therapeutics Monoclonal Antibody , by Region USD Million (2020-2025)
  • Table 126. mRNA Vaccines & Therapeutics Others , by Region USD Million (2020-2025)
  • Table 127. South America mRNA Vaccines & Therapeutics, by Country USD Million (2020-2025)
  • Table 128. South America mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 129. South America mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 130. South America mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 131. Brazil mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 132. Brazil mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 133. Brazil mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 134. Argentina mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 135. Argentina mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 136. Argentina mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 137. Rest of South America mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 138. Rest of South America mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 139. Rest of South America mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 140. Asia Pacific mRNA Vaccines & Therapeutics, by Country USD Million (2020-2025)
  • Table 141. Asia Pacific mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 142. Asia Pacific mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 143. Asia Pacific mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 144. China mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 145. China mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 146. China mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 147. Japan mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 148. Japan mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 149. Japan mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 150. India mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 151. India mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 152. India mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 153. South Korea mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 154. South Korea mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 155. South Korea mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 156. Taiwan mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 157. Taiwan mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 158. Taiwan mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 159. Australia mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 160. Australia mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 161. Australia mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 162. Rest of Asia-Pacific mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 163. Rest of Asia-Pacific mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 164. Rest of Asia-Pacific mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 165. Europe mRNA Vaccines & Therapeutics, by Country USD Million (2020-2025)
  • Table 166. Europe mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 167. Europe mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 168. Europe mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 169. Germany mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 170. Germany mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 171. Germany mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 172. France mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 173. France mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 174. France mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 175. Italy mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 176. Italy mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 177. Italy mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 178. United Kingdom mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 179. United Kingdom mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 180. United Kingdom mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 181. Netherlands mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 182. Netherlands mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 183. Netherlands mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 184. Rest of Europe mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 185. Rest of Europe mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 186. Rest of Europe mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 187. MEA mRNA Vaccines & Therapeutics, by Country USD Million (2020-2025)
  • Table 188. MEA mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 189. MEA mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 190. MEA mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 191. Middle East mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 192. Middle East mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 193. Middle East mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 194. Africa mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 195. Africa mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 196. Africa mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 197. North America mRNA Vaccines & Therapeutics, by Country USD Million (2020-2025)
  • Table 198. North America mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 199. North America mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 200. North America mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 201. United States mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 202. United States mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 203. United States mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 204. Canada mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 205. Canada mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 206. Canada mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 207. Mexico mRNA Vaccines & Therapeutics, by Type USD Million (2020-2025)
  • Table 208. Mexico mRNA Vaccines & Therapeutics, by Application USD Million (2020-2025)
  • Table 209. Mexico mRNA Vaccines & Therapeutics, by Mechanism of Action USD Million (2020-2025)
  • Table 210. mRNA Vaccines & Therapeutics: by Type(USD/Units)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global mRNA Vaccines & Therapeutics: by Type USD Million (2014-2019)
  • Figure 5. Global mRNA Vaccines & Therapeutics: by Application USD Million (2014-2019)
  • Figure 6. Global mRNA Vaccines & Therapeutics: by Mechanism of Action USD Million (2014-2019)
  • Figure 7. South America mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 9. Europe mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 10. MEA mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 11. North America mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 12. Global mRNA Vaccines & Therapeutics: by Type USD/Units (2014-2019)
  • Figure 13. Global mRNA Vaccines & Therapeutics share by Players 2019 (%)
  • Figure 14. Global mRNA Vaccines & Therapeutics share by Players (Top 3) 2019(%)
  • Figure 15. Global mRNA Vaccines & Therapeutics share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Argos Therapeutics (U.S) Revenue, Net Income and Gross profit
  • Figure 18. Argos Therapeutics (U.S) Revenue: by Geography 2019
  • Figure 19. AstraZeneca (UK) Revenue, Net Income and Gross profit
  • Figure 20. AstraZeneca (UK) Revenue: by Geography 2019
  • Figure 21. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Bayer (Germany) Revenue: by Geography 2019
  • Figure 23. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Boehringer Ingelheim (Germany) Revenue: by Geography 2019
  • Figure 25. CRISPR Therapeutics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. CRISPR Therapeutics (Switzerland) Revenue: by Geography 2019
  • Figure 27. CureVac (Germany) Revenue, Net Income and Gross profit
  • Figure 28. CureVac (Germany) Revenue: by Geography 2019
  • Figure 29. ETheRNA immunotherapies (Belgium) Revenue, Net Income and Gross profit
  • Figure 30. ETheRNA immunotherapies (Belgium) Revenue: by Geography 2019
  • Figure 31. Ethris (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Ethris (Germany) Revenue: by Geography 2019
  • Figure 33. In-Cell-Art (France) Revenue, Net Income and Gross profit
  • Figure 34. In-Cell-Art (France) Revenue: by Geography 2019
  • Figure 35. Intellia Therapeutics (U.S) Revenue, Net Income and Gross profit
  • Figure 36. Intellia Therapeutics (U.S) Revenue: by Geography 2019
  • Figure 37. Global mRNA Vaccines & Therapeutics: by Type USD Million (2020-2025)
  • Figure 38. Global mRNA Vaccines & Therapeutics: by Application USD Million (2020-2025)
  • Figure 39. Global mRNA Vaccines & Therapeutics: by Mechanism of Action USD Million (2020-2025)
  • Figure 40. South America mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 41. Asia Pacific mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 42. Europe mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 43. MEA mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 44. North America mRNA Vaccines & Therapeutics Share (%), by Country
  • Figure 45. Global mRNA Vaccines & Therapeutics: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Argos Therapeutics (U.S)
  • AstraZeneca (UK)
  • Bayer (Germany)
  • Boehringer Ingelheim (Germany)
  • CRISPR Therapeutics (Switzerland)
  • CureVac (Germany)
  • ETheRNA immunotherapies (Belgium)
  • Ethris (Germany)
  • In-Cell-Art (France)
  • Intellia Therapeutics (U.S)
Additional players considered in the study are as follows:
Janssen (Belgium) , Kernal Biologics (U.S) , MaxCyte (U.S) , Moderna Therapeutics (U.S) , Novartis (Switzerland) , Precision NanoSystems (Canada) , RaNa Therapeutics (U.S)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation